Definium Therapeutics, Inc.
Reads like this one publish minutes after the filing lands on EDGAR. Get them as JSON over the API or inside your AI agent over MCP.
No SEC Form 4 filings for $DFTX in the last 30 days.
See all $DFTX insider activity →Definium Therapeutics (DFTX) granted options for 93,320 shares to six new employees. The options were approved by the Compensation Committee on October 23, 2026, under NASDAQ Rule 5635(c)(4) and the 2026 Inducement Plan. Definium focuses on psychedelic-based psychiatric treatments and is headquartered in New York.
RBC Capital reiterated an Outperform rating for Definium Therapeutics (DFTX) with a $66 price target, citing strong Phase III trial data for anxiety and depression treatments. Despite a 30% share price drop, RBC sees potential for approval and $2.5B peak revenue. Other analysts also raised price targets following positive trial results.
Definium Therapeutics (DFTX) stock rose 2.2% after JPMorgan initiated coverage with an Overweight rating and $84 price target, citing DT120 ODT's potential in neuropsychiatry. The company has 18 buy ratings and is targeting FDA submission in early 2027. Broader market gains also supported the rise.
Over the past 7 days, AlphAI's AI scored 1 news story mentioning DFTX (Definium Therapeutics, Inc.). Coverage has been balanced: 0 bullish, 1 neutral, and 0 bearish.
Recent DFTX coverage spans technology, financial news and insider activity.
The option grant may cause slight dilution but is unlikely to move the stock significantly.
Positive Phase III results are likely to drive approval expectations and boost the stock.
The upgrade adds institutional credibility and a higher target, likely pushing the stock higher.
The insider sale may signal reduced confidence or liquidity need, potentially pressuring the stock lower.
The insider sale may signal negative sentiment or liquidity need, potentially pressuring the stock.
AlphAI scores every news story that mentions DFTX with an AI model for sentiment and relevance, and aggregates insider trades from Definium Therapeutics, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Definium Therapeutics (DFTX) granted options for 93,320 shares to six new employees. The options were approved by the Compensation Committee on October 23, 2026, under NASDAQ Rule 5635(c)(4) and the 2026 Inducement Plan. Definium focuses on psychedelic-based psychiatric treatments and is headquartered in New York.
1 min readRBC Capital reiterated an Outperform rating for Definium Therapeutics (DFTX) with a $66 price target, citing strong Phase III trial data for anxiety and depression treatments. Despite a 30% share price drop, RBC sees potential for approval and $2.5B peak revenue. Other analysts also raised price targets following positive trial results.
1 min readDefinium Therapeutics (DFTX) stock rose 2.2% after JPMorgan initiated coverage with an Overweight rating and $84 price target, citing DT120 ODT's potential in neuropsychiatry. The company has 18 buy ratings and is targeting FDA submission in early 2027. Broader market gains also supported the rise.
1 min readBarrow Robert (Chief Executive Officer) sold 31,550 shares of Definium Therapeutics, Inc. (DFTX) at $36.57 ($1.15M total) on 2026-09-25 under a Rule 10b5-1 trading plan.
1 min readSullivan Mark (Chief Legal Officer) sold 14,051 shares of Definium Therapeutics, Inc. (DFTX) at $36.57 ($0.51M total) on 2026-09-25 under a Rule 10b5-1 trading plan.
1 min readDefinium Therapeutics (DFTX) officer Mark Sullivan proposed selling 14,051 shares, valued at $516,093, on September 25, 2026. The shares are restricted stock vesting under a registered plan. Previously, 13,008 shares were sold on June 25, 2026, for $548,027. Morgan Stanley Smith Barney LLC is the broker.
1 min readDefinium Therapeutics (DFTX) presented phase III data for DT120, showing statistically significant results in treating generalized anxiety disorder and major depressive disorder. The drug demonstrated placebo-adjusted improvements of 5.4, 5.1, and 8.1 points in respective studies, with rapid clearance. The company is preparing for pre-NDA talks with the FDA to discuss filing strategies. Response and remission rates were lower than phase II but still clinically meaningful.
2 min readDefinium Therapeutics (DFTX) reported positive Phase 3 trial results for its LSD-based anxiety drug, DT120. The trial showed a 5.1-point improvement over placebo, similar to its previous trial. Psychedelic stocks often move together, and Definium's success could impact the broader sector. Hedge fund holdings of DFTX have increased, indicating growing institutional confidence.
2 min readDefinium Therapeutics (DFTX) reported positive Phase III results for DT120 in treating anxiety, with 32% of patients showing significant improvement vs. 14% on placebo. The drug was well-tolerated, and the company plans to meet with the FDA in Q4, aiming for an NDA submission in early 2027. Definium has $1.1B in cash and is preparing for commercialization.
2 min readDefinium Therapeutics (DFTX) reported positive Phase 3 trial results for DT120 ODT in treating generalized anxiety disorder. The stock has surged 184.53% year-to-date, with a fair value estimate of $71.65, suggesting a 46% undervaluation. The company faces risks due to its pre-revenue status and reliance on DT120's success, with key Phase 3 readouts expected in 2026.
3 min read
